F	axed prescriptions will only be a	accepted from a prescriber. Patie	ents must bring an original presci	ription to the	e pharmacy, and ca	nnot fax these refe	rral forms to Senderra.				
	3	Ankylosing Spondylitis Enrollment Form					NPI:				
	'	Linolinentioni	Supervising Physician:				NPI:				
OFNIE		Physician Offices Call: 855-460-7928	Address:				Tax ID:				
2FINF	PERRA		Phone:		Fax:						
Specialt	y Pharmacy	Fax: 888-777-5645	Contact:								
1301 E. Arapaho Rd., Ste. 101 Richardson, TX 75081											
This prescription form is to be sent & received via fax											
PATIENT INFORMATION Name: □ M □ F □ Trans M □ Trans F □ Other DOB: , , , SS#:											
Street: City: State: ZIP:											
Phone: Alt. Phone:											
PRESCRIPTION											
Has the patient received a loading dose/starter kit? Yes Start Date:// DNo Ship to: Driections & Quantity Directions & Quantity Refill:											
Drug		☐ INITIAL: Inject 400 mg SQ at weeks 0, 2, & 4 (Quantity: 6)						Retills			
Cimzia [®]	Pre-filled Syringe Vials	MAINTENANCE: Inject 400 mg SQ every 4 weeks (Quantity: 2)									
		MAINTENANCE: Inject 200 mg SQ every other week (Quantity: 2)									
Cosentyx®	Sensoready Pen	☐ INITIAL: Inject 150 mg S	Q at week 0, 1, 2, 3, & 4		□ MAINTENANG	CE: Inject 150 mg	SQ every 4 weeks	I			
		(Quantity: 5) ***Dosing intended for Non-Radiographic Axial Spondyloarthritis*** (Quantity: 1) ***Dosing intended for Non-Radiographic Axial Spondyloarthritis***									
	Pre-filled Syringe	☐ INITIAL: Inject 300 mg SQ at week 0, 1, 2, 3, & 4 ☐ MAINTENANCE: Inject 300 mg SQ every 4 weeks									
	SureClick® Pen	(Quantity: 10) (Quantity: 2)									
Enbrel [®]	Mini® with AutoTouch®	□ Inject 50 mg SQ every week (Quantity: 4)									
	50 mg Pre-filled Syringe										
Li.mira®	Pen Pre-filled Syringe										
Humira® ☐ Pen Citrate Free ☐ Pre-filled Syringe ☐ Inject 40 mg SQ every other week (Quantity: 2)											
Rinvog®	15 mg Tablets	☐ Take 15 mg PO once daily (Quantity: 30)									
Rinvoq	SmartJect® Pen										
Simponi®	☐ Pre-filled Syringe	☐ Inject 50 mg SQ once a month (Quantity: 1)									
Taltz [®]	☐ Autoinjector ☐ Pre-filled Syringe	☐ INITIAL: Inject 160 mg SQ at week 0 (Quantity: 2)									
		MAINTENANCE: Inject 80 mg SQ every 4 weeks (Quantity: 1)									
		Inject 80 mg SQ every 4 weeks (Quantity: 1) ***Dosing intended for Non-Radiographic Axial Spondyloarthritis (Nr-axSpA)***									
Xeljanz [®]	5 mg Tablets	Take 5 mg PO twice daily (Quantity: 60)									
Xeljanz [®] XR	11 mg Tablets	Take 11 mg PO once daily (Quantity: 30)									
MEDICAL INFORMATION											
PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY PREVIOUS THERAPIES: Tried & Failed (Duration): Not Tolerated: Contraindication:											
☐ _{Methotrexate})									
☐ Enbrel											
☐ _{Humira}											
 □											
M45.9 Ankylosing Spondylitis, Unspecified M45											
M45.A0 Non-Radiographic Axial Spondyloarthritis (Nr-axSpA) of unspecified sites in spine											
□ M46.8											
Date of Diagnosi	s:/	A	llergies:								
Active TB is ruled out: \square_{Yes} \square_{No} Date: / / Hep B ruled out/treated: \square_{Yes} \square_{No} Date: / /											
HLA-B27 Positive: \square_{Yes} \square_{No} Date:/											
Additional Clinical Information:											
			INJECTION TRAINING								
Patient has received pen and injection training Physician's office to provide injection training Senderra to coordinate injection training PRESCRIBER SIGNATURE											
To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra to serve as your prior authorization designated agent in dealing with medical and prescription insurance											
companies, and co-pay assistance foundations. Prescriber:											
						Date:					
IMPORTANT: THE C	ov in intended to be delicered	ply to the newest addresses "	CONFIDENTIALITY NOT		on or over the	dicologues and the	onligable law. If you are and "	nomed			
IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.											